Prognostic Significance of Mutation Type and Chromosome Fragility in Fanconi Anemia

NCT ID: NCT06490510

Last Updated: 2024-07-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

227 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-05-16

Study Completion Date

2024-06-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to analyze the data included in the Spanish Registry of Patients with Fanconi anemia to better understand the natural history of the disease, identify genetic risk and prognostic factors, and identify potential therapeutic strategies.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fanconi Anemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients in the Spanish Registry of Patients with Fanconi Anemia

Exclusion Criteria

\-
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jordi Surrallés, PhD

Role: PRINCIPAL_INVESTIGATOR

Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau - IIB Sant Pau

Barcelona, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

References

Explore related publications, articles, or registry entries linked to this study.

Ramirez MJ, Pujol R, Minguillon J, Bogliolo M, Persico I, Cavero D, de la Cal A, Rio P, Navarro S, Casado JA, Bailador A, de la Fuente AS, de Heredia ML, Almazan F, Antelo ML, Argiles B, Badell I, Baragano M, Belendez C, Bermudez M, Bernues M, Buedo MI, Carrasco E, Catala A, Costa D, Cuesta I, Fernandez-Delgado R, Fernandez-Teijeiro A, Figuera A, Garcia M, Gondra A, Gonzalez M, Muniz SG, Hernandez-Rodriguez I, Ibanez F, Kelleher NJ, Lendinez F, Lopez M, Lopez-Almaraz R, Marchante I, Mendoza C, Nieto J, Ojeda E, Payan-Pernia S, Pelaez I, de Soto IP, Portugal R, Ramos-Arroyo MA, Regueiro A, Rodriguez A, Rosell J, Saez R, Sanchez J, Sanchez M, Senent M, Tapia M, Trujillo-Quintero JP, Vagace JM, Verdu-Amoros J, Verdugo V, Vidales I, Villarreal J, Diaz-de-Heredia C, Sevilla J, Bueren JA, Surralles J. Prognostic significance of mutation type and chromosome fragility in Fanconi anemia. Am J Hematol. 2025 Feb;100(2):272-284. doi: 10.1002/ajh.27520. Epub 2024 Nov 19.

Reference Type DERIVED
PMID: 39562502 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IIBSP-PFA-2024-47

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Gene Therapy for Fanconi Anemia, Complementation Group A
NCT04248439 ACTIVE_NOT_RECRUITING PHASE2